Media headlines about Medtronic (NYSE:MDT) have been trending positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than 6,000 blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medtronic earned a news sentiment score of 2.86 on their scale. InfoTrie also gave news stories about the medical technology company an news buzz score of 1 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the near future.
These are some of the media headlines that may have effected Medtronic’s ranking:
- Hedge Funds Are Betting On Medtronic, Inc. (MDT) (feedproxy.google.com)
- Medtronic PLC (MDT) Expected to Announce Earnings of $1.24 Per Share (americanbankingnews.com)
- Medtronic Canada Recognized as One of Greater Toronto’s Top Employers for 2019 (finance.yahoo.com)
- Undervalued Medtronic Looks Like a Healthy Buy (finance.yahoo.com)
- Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2019 (finance.yahoo.com)
MDT has been the subject of several analyst reports. Needham & Company LLC raised Medtronic from a “buy” rating to a “strong-buy” rating and lifted their price objective for the company from $103.00 to $119.00 in a report on Monday, August 13th. Oppenheimer reaffirmed a “buy” rating and issued a $104.00 price objective on shares of Medtronic in a report on Tuesday, August 21st. Stifel Nicolaus lifted their price target on Medtronic from $87.00 to $96.00 and gave the company a “hold” rating in a research note on Wednesday, August 22nd. Morgan Stanley lifted their price target on Medtronic from $95.00 to $105.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 22nd. Finally, Wells Fargo & Co lifted their price target on Medtronic from $95.00 to $101.00 and gave the company a “market perform” rating in a research note on Wednesday, August 22nd. Seven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $104.87.
Shares of MDT opened at $94.24 on Friday. Medtronic has a 52-week low of $76.41 and a 52-week high of $100.15. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.11 and a current ratio of 2.56. The firm has a market capitalization of $129.25 billion, a PE ratio of 19.76, a price-to-earnings-growth ratio of 2.50 and a beta of 0.96.
Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 20th. The medical technology company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.15 by $0.07. The business had revenue of $7.48 billion for the quarter, compared to analyst estimates of $7.35 billion. Medtronic had a return on equity of 13.51% and a net margin of 7.44%. Medtronic’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS. Equities research analysts expect that Medtronic will post 5.13 earnings per share for the current year.
In related news, EVP Geoffrey Martha sold 49,799 shares of the business’s stock in a transaction on Monday, September 24th. The stock was sold at an average price of $97.93, for a total transaction of $4,876,816.07. Following the sale, the executive vice president now owns 87,872 shares in the company, valued at approximately $8,605,304.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.28% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/12/08/medtronic-mdt-earns-news-sentiment-score-of-2-86.html.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
Recommended Story: What are catch-up contributions?
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.